Biomarker ID | 755 |
PMID | 21917134 |
Year | 2011 |
Biomarker | CEP55 |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated with high Gleason Score |
Odds Ratio/Hazard Ratio/Relative Risk | [GS (3+4): HR = 22.07 (95% CI: 2.82, 172.74)] ; [GS (4+3): HR = 28.90 (95% CI:3.34, 250.28)] ; [GS (8-10): HR = 29.25 (95% CI: 3.82, 224.08)] |
Effect on Pathways | Pathways Include:-Cytoskeletal Signaling,DNA Damage |
Experiment | Gleason Score (≤6, (3+4), (4+3), 8-10) |
Type of Biomarker | Prognostic |
Cohort | Specimens from 72 clinically localized PCa cases with follow-up data (29 without recurrence and 43 with recurrence) and 17 clinically localized PCa without follow-up data were collected and frozen at the time of radical prostatectomy |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | For Hazrard Ratio: (p = 0.003) |
Method Used | real-time PCR |
Clinical | No |
Remarks | Multivariate Analysis |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | CEP55 |